LHFPL1

Across TCGA pan-cancer cohorts, LHFPL1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LHFPL1 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher LHFPL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LHFPL1 expression acts as an unfavorable survival marker.

SARC, LIHC, and LUSC are the cancer types where LHFPL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.147	0.747	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.011	0.716	<.001	12	view →
LUSC	DFS	Median	All	0.174	0.645	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LHFPL1–SARC (OS)

Open the SARC breakdown →